Document Detail


Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
MedLine Citation:
PMID:  10699346     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this study was to determine whether the antibodies raised in burn patients by active immunization with a Pseudomonas aeruginosa OMPs vaccine have a protective efficacy against infection with P. aeruginosa. The binding patterns with P. aeruginosa OMPs of immunized burn patient sera were similar to the sera of immunized healthy humans as determined by immunoblot and immunoprecipitation analyses. The sera pooled from immunized burn patients after three immunizations showed a significantly higher opsonophagocytic-killing activity than the corresponding pre-immune sera, while the sera from unimmunized patients collected at the same day did not. Passive immunization of mice with post-immune sera of burn patients significantly enhanced the survival rate upon a lethal challenge with P. aeruginosa compared to the pre-immune sera, indicating the protective ability of the antibodies induced in burn patients by immunization. These results suggest that anti-P. aeruginosa OMPs antibodies elicited in burn patients by active immunization are protective against infection with P. aeruginosa, and provide a rational for further development of the vaccine for prevention against P. aeruginosa infection in burn patients.
Authors:
N G Lee; S B Jung; B Y Ahn; Y H Kim; J J Kim; D K Kim; I S Kim; S M Yoon; S W Nam; H S Kim; W J Park
Related Documents :
7622906 - Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: rel...
2905596 - Role of maternal antibody in protection from hemorrhagic fever with renal syndrome viru...
19869316 - Immunological properties of a typical (s-producing) and a degraded (non-s-producing) st...
2760276 - Studies of the protective effect of different fractions of sera from pigs immune to str...
1583116 - Indirect hemagglutination assay for diagnosis of escherichia coli o157 infection in pat...
10518046 - Effect of acetylation (o-factor 5) on the polyclonal antibody response to salmonella ty...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Vaccine     Volume:  18     ISSN:  0264-410X     ISO Abbreviation:  Vaccine     Publication Date:  2000 Mar 
Date Detail:
Created Date:  2000-05-09     Completed Date:  2000-05-09     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  8406899     Medline TA:  Vaccine     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1952-61     Citation Subset:  IM    
Affiliation:
R&D Center of Bioscience, Institute of Science and Technology, Cheiljedang Corp., Ichon, Kyonggi, South Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Bacterial / biosynthesis*,  blood,  therapeutic use
Antigen-Antibody Reactions
Bacterial Outer Membrane Proteins / immunology,  metabolism,  therapeutic use*
Bacterial Vaccines / immunology,  therapeutic use*
Burns / immunology*,  microbiology*
Humans
Immunization, Passive / methods
Immunoglobulin G / biosynthesis,  blood,  immunology
Male
Mice
Mice, Inbred ICR
Opsonin Proteins / immunology
Phagocytosis / immunology
Pseudomonas Infections / prevention & control*
Pseudomonas aeruginosa / immunology*
Rabbits
Vaccines, Inactivated / immunology,  therapeutic use
Chemical
Reg. No./Substance:
0/Antibodies, Bacterial; 0/Bacterial Outer Membrane Proteins; 0/Bacterial Vaccines; 0/Immunoglobulin G; 0/Opsonin Proteins; 0/Vaccines, Inactivated

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in...
Next Document:  Quantification of the number of cytotoxic T cells specific for an immunodominant HCV-specific CTL ep...